Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...

On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...

Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and ...

BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...

The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.

Novo Nordisk A/S (NVO), based in Bagsvaerd, Denmark, engages in the R&D, manufacturing, and distribution of pharmaceutical products specializing in treating diabetes, obesity, and rare diseases. The ...

Eli Lilly (Indianapolis, IN, US) and Novo Nordisk (Bagsvaerd, Denmark) have announced that the supply of their GLP-1 weight loss drugs has improved, with the FDA shortages database now reporting ...

Novo Nordisk is headquartered in Bagsvaerd, Denmark. For a complete picture of NNC-04870111’s drug-specific PTSR and LoA scores, buy the report here. GlobalData, the leading provider of industry ...